Drugs / Brazikumab
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05033431 | Oct 2021 → Oct 2022 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT04277546 | Mar 2020 → Oct 2023 | ulcerative colitis | AstraZeneca | Terminated | No outcome recorded |
| Phase 2 | NCT03616821 | Aug 2018 → Oct 2023 | ulcerative colitis | AstraZeneca | Terminated | No outcome recorded |
| Phase 2 | NCT02574637 | Jan 2016 → Jul 2017 | Crohn disease | AstraZeneca | Terminated | No outcome recorded |
| Phase 2 | NCT01714726 | Feb 2013 → May 2014 | Crohn disease | AstraZeneca | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03759288 | Dec 2018 → Oct 2023 | Crohn disease | AstraZeneca | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03961815 | Jan 2020 → Sep 2023 | Crohn disease | AstraZeneca | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | brazikumab | “brazikumab (MEDI2070), a human monoclonal antibody” PMID 38124112 ↗ Dec 2023 |
| Known as | MEDI2070 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01714726 ↗ |
| Action | Inhibit | “anti-p19 subunit inhibitor of interleukin-23” PMID 38124112 ↗ Dec 2023 |
| Modality | Monoclonal antibody | “a human monoclonal antibody” PMID 38124112 ↗ Dec 2023 |
| Route | Intravenous | “administered as intravenous infusion” NCT01714726 ↗ |